Dosing (DRd)
Dosing schedule for DARZALEX FASPRO® + Rd and DARZALEX® + Rd
Once-monthly dosing over time—a key milestone for newly diagnosed, transplant-ineligible patients with multiple myeloma1,2*
Dosing schedule with DRd regimen†
Starting at Cycle 7 (~6 months), patients will transition to approximately once-monthly dosing for DARZALEX FASPRO® or DARZALEX® + Rd
Continue DRd until disease progression or unacceptable toxicity
DARZALEX FASPRO® in combination with lenalidomide and dexamethasone (4-week cycle) has the same dosing schedule as DARZALEX® in combination with lenalidomide and dexamethasone.1,2‡
For more detailed information on dosing and administration, including management of infusion-related reactions (IRRs) and administration-related reactions (ARRs), download the dosing and administration guide for DARZALEX FASPRO® and DARZALEX®
DARZALEX FASPRO® is administered subcutaneously over ~3 to 5 minutes while DARZALEX® is given intravenously over 7 hours for the first infusion, 4 hours for the second infusion, and 3 hours for subsequent infusions (median).1,2
DRd=DARZALEX FASPRO®/DARZALEX® (D) + lenalidomide (R) + dexamethasone (d); Rd=lenalidomide (R) + dexamethasone (d).
First dose of the every-2-week dosing schedule is given at Week 9. First dose of the every-4-week dosing schedule is given at Week 25.1,2
*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® or DARZALEX® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.
†Cycle=28 days.
‡The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.1,2
Dosing and administration guide for DARZALEX FASPRO® and DARZALEX®
References:
- DARZALEX FASPRO® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.